Tenderwize
Back to tender search

Open-House Discount Contracts for Infliximab (Subcutaneous Injection)

Techniker Krankenkasse·Hamburg, Germany·Deadline May 30, 2028 · 648 days left·Open·Supplies
Sign up to saveOpen documents
Structured notice only
Original notice title

Germany – Pharmaceutical products – Open-House-Biologika-Rabattverträge 2026-10 - Infliximab (Darreichungsform zur subkutanen Injektion)

40/100

Opportunity Score

Needs reviewLow complexity
SuppliesOpen
Why this score?

Opportunity

40 / 100

Complexity

30 / 100

Risk factors

No estimated contract value, framework maximum value, or budget provided. Revenue potential is unknown.

Contract ends automatically upon patent expiry or loss of market exclusivity. Could be terminated earlier than the max...

Deep Portfolio Analysis

Deep Company Fit Analysis

Uses:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Overview

Moderate opportunity

Key Facts

  • Supplies contract
  • 1 lot
  • Duration until May 2028
  • Conclusion of discount contracts for Infliximab (subcutaneous injection) with multiple pharmaceutical entrepreneurs.
  • Uniform contract terms; no individual negotiations.
Show full summary

Open-House procedure for discount contracts (Rabattverträge) under § 130a Abs. 8 SGB V for the active substance Infliximab (subcutaneous injection). No competitive selection; any qualified pharmaceutical entrepreneur can join. No estimated value provided. The lead buyer is Techniker Krankenkasse, with several other German statutory health insurance funds. The contract term is up to 24 months starting June 1, 2026, ending May 31, 2028. Participation is open throughout the contract term. No procurement documents were analyzed.

Risks

No estimated contract value, framework maximum value, or budget provided. Revenue potential is unknown.

Contract ends automatically upon patent expiry or loss of market exclusivity. Could be terminated earlier than the max...

Analysis may be incomplete

Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.

Key Requirements

Technical

  • Must be a pharmaceutical entrepreneur as defined by § 4 Abs. 18 AMG.
  • Must hold a valid marketing authorization for the product or be entitled to place the product on the market.

Administrative

  • Must provide a self-declaration on authorization and company (Anlage 4).

Requirements may be incomplete.

Buyer

Location

Hamburg, DEU

Identifier

992-80116-93

Activity

Health

Lots (1)

LOT-0001

Open-House Discount Contracts for Infliximab (Subcutaneous Injection)

Conclusion of discount contracts for the active substance Infliximab (subcutaneous injection) with any eligible pharmaceutical entrepreneur under an open-house model. No exclusivity; uniform conditions apply.

SuppliesEU fundedElectronic submission

Location

DE600, Germany

Duration

May 2026 - May 2028

Category

Pharmaceutical products

Deadline

Deadline May 30, 2028

Procurement Details

Publication date
19 Apr 2026
Languages
German

Reference metadata

Legal basis
32014L0024

Reference IDs

Tender ID
266368-2026

Documents (1)

Procurement document 1

Similar tenders

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Belgium – Pharmaceutical products – Antimycotica

Aug 27

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3

France – Pharmaceutical products – 26-10 : ACCORD-CADRE DE FOURNITURE DE MÉDICAMENTS 2026

Aug 21

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9